If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.65    0.025 (1.54%)
Bid:
1.35
Ask:
2.30
Spread: 0.95 (70.37%)
Market Cap: £5.79m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Director Dealing

31 Jul 2008 16:13

For Immediate Release 31 July 2008

PROTEOME SCIENCES plc

("Proteome Sciences" or the "Company")

PRESS RELEASE

DIRECTORS' SHAREHOLDINGS

Proteome Sciences announces that on 31 July 2008 it granted a conditional award of 1,882,500 Ordinary Shares of 1p each in the Company ("Ordinary Shares") to C.D.J. Pearce, Chief Executive and of 1,170,000 Ordinary Shares of 1p each to J.L. Malthouse, Finance Director, under its Long-Term Incentive Plan ("LTIP") based on a closing mid-market price on 30 July 2008 of 20p per Ordinary Share.

In accordance with the rules of the LTIP, the Ordinary Shares awarded will vest 3 years after the date of grant subject to the Company achieving a target total shareholder return (TSR) over a three-year performance period relative to the AIM Healthcare Index at the start of that period. TSR is the aggregate of share price growth and the value of dividend payments during the performance period. No shares will be released unless the Company's TSR performance exceeds that of the index, in which case 30% of the award will vest with full vesting only if the Company's TSR performance exceeds that of the Index by 10%, with a pro-rata award between 30% and 100% for each percentage point of out-performance up to 10%.

The Remuneration Committee of the Board of Directors believes that today's award under the LTIP aligns the interests of shareholders with those of the executive by making the award dependent on the success of management in delivering superior returns to shareholders.

C.D.J. Pearce currently holds 6,538,075 shares in the Company, and has a previous conditional award under the LTIP of up to 504,523 shares.

J.L. Malthouse currently holds 625,000 shares in the Company, and has a previous conditional award under the LTIP of up to 470,352 shares.

Ends

Proteome Sciences plc

Christopher Pearce James Malthouse

Chief Executive Officer Finance Director

christopher.pearce@proteomics.com james.malthouse@proteomics.com

Tel: +44 (0)1932 865065

Nominated Adviser

Landsbanki Securities (UK) Limited

Shaun Dobson / Claes SpĴng Tel: +44 (0)20 7426 9000

vendor
Date   Source Headline
20th Aug 20127:00 amRNSRe Agreement
29th Jun 201212:10 pmRNSAGM Statement
7th Jun 20123:10 pmRNSAnnual Financial Report
29th May 20127:00 amRNSFinal Results
30th Apr 20127:00 amRNSTotal Voting Rights
5th Apr 20127:00 amRNSStroke biomarker license to Randox
29th Mar 20125:11 pmRNSBlock Admission Return
28th Mar 20127:00 amRNSCompletion of Alzheimer's Plasma Biomarker Study
19th Mar 201210:00 amRNSEuroHYP EU Grant Award for Stroke
8th Mar 20128:55 amRNSHolding(s) in Company
5th Mar 20127:00 amRNSChange of Adviser
24th Feb 20124:24 pmRNSDirector/PDMR Shareholding
31st Jan 20127:00 amRNSTotal Voting Rights
18th Jan 20127:00 amRNSAdditional Listing
22nd Dec 20117:00 amRNSPromising hits against Alzheimer's Target
24th Nov 20117:00 amRNSNovel In Vitro Assays Developed
8th Nov 20113:39 pmRNSDirector Holdings
7th Oct 20117:00 amRNSBlock Admission Return
30th Sep 20117:00 amRNSInterim Results 2011
11th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20111:33 pmRNSNotification of Major interest in Shares
9th Aug 20117:00 amRNSProteome Sciences as Preferred Supplier
26th Jul 20117:00 amRNSAppointment of VP Business Development
14th Jul 20117:00 amRNSCollaboration with Buck Institute - biomarket test
7th Jul 20117:00 amRNSCollaboration Agreement
29th Jun 20111:31 pmRNSAGM Statement
28th Jun 20118:12 amRNSDenamic ?6.9m EU Framework Grant
6th Jun 20111:21 pmRNSAnnual Financial Report
27th May 20117:00 amRNSFinal Results
27th May 20117:00 amRNSFinal Results
29th Mar 20117:00 amRNSTakeda Research Contract
28th Mar 20114:38 pmRNSBlocklisting Interim Review
8th Mar 20114:40 pmRNSSecond Price Monitoring Extn
8th Mar 20114:35 pmRNSPrice Monitoring Extension
31st Jan 20117:00 amRNSContract for Biomarker Services with Eisai
10th Jan 20113:39 pmRNSDirector/PDMR Shareholding
23rd Dec 20107:00 amRNSDirectorate Change
20th Dec 20107:00 amRNSResearch Contract
30th Nov 20107:00 amRNSTrading Statement
23rd Nov 201010:30 amRNSBlocklisting Interim Review
23rd Nov 20109:46 amRNSHolding(s) in Company
15th Nov 20107:00 amRNSProteome Sciences form alliance with ICON
14th Oct 20103:00 pmRNSHolding(s) in Company
30th Sep 20107:00 amRNSHalf Yearly Report
28th Sep 20107:00 amRNSStatement re Warranty Claim
23rd Sep 20107:00 amRNSCollaboration with Thermo Fisher
21st Jul 20104:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSProduct Launch
6th Jul 20101:11 pmRNSDirector/PDMR Shareholding
1st Jul 201011:10 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.